Document Detail

Detection of Activated Leukocyte Cell Adhesion Molecule in the Serum of Breast Cancer Patients and Implications for Prognosis.
MedLine Citation:
PMID:  22555284     Owner:  NLM     Status:  Publisher    
Objective: Conflicting results have been reported about activated leukocyte cell adhesion molecule (ALCAM) expression in breast cancer and its prognostic value. Little is known about the role of ALCAM levels in the serum of breast cancer patients. Methods: We analyzed soluble ALCAM (sALCAM) levels in the serum of 157 primary breast cancer patients and 48 healthy women by ELISA. In addition, we determined ALCAM protein expression by Western blot analysis (n = 120) and mRNA expression by cDNA microarray analysis (n = 115) in the tumor tissue of corresponding patients. Results: sALCAM levels differed between patients and healthy controls (median 24.2 vs. 18.9 ng/ml, p < 0.001). We observed no correlation between serum levels and protein or mRNA expression in corresponding tumors (r < 0.1, p = n.s.). sALCAM levels were not correlated with histological type, grading, tumor stage, or patient age, but elevated sALCAM levels were associated with shorter disease-free survival (HR = 1.97, 95% CI 1.01-3.2, p = 0.043). Conclusions: Our results indicate that sALCAM can be detected in the serum of patients with primary breast cancer. Elevated serum levels might indicate more aggressive tumor behavior as they might be an independent factor for a worse prognosis in breast cancer patients.
Isabell Witzel; Christine Schröder; Volkmar Müller; Hilke Zander; Michael Tachezy; Maike Ihnen; Fritz Jänicke; Karin Milde-Langosch
Related Documents :
23562674 - Vimentin expression predicts the occurrence of metastases in non small cell lung carcin...
22583364 - Immunohistochemical verification of ductal differentiation in prostate cancer.
20698144 - Myeloid sarcoma involving the breast.
24330704 - Eugenol triggers apoptosis in breast cancer cells through e2f1/survivin down-regulation.
23569364 - Long-term efficacy and safety of exemestane in the treatment of breast cancer.
17473204 - Cd4+cd25+ regulatory t-cell frequency in her-2/neu (her)-positive and her-negative adva...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-5-03
Journal Detail:
Title:  Oncology     Volume:  82     ISSN:  1423-0232     ISO Abbreviation:  -     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-5-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0135054     Medline TA:  Oncology     Country:  -    
Other Details:
Languages:  ENG     Pagination:  305-312     Citation Subset:  -    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Towards the use of cannabinoids as antitumour agents.
Next Document:  Ultra-broadband near-infrared excitable upconversion core/shell nanocrystals.